Last reviewed · How we verify
TV-46000
TV-46000 is a small molecule in development for the treatment of atrial fibrillation.
TV-46000 is a small molecule in development for the treatment of atrial fibrillation. Used for Atrial fibrillation for stroke prevention.
At a glance
| Generic name | TV-46000 |
|---|---|
| Also known as | Risperidone |
| Sponsor | Teva Branded Pharmaceutical Products R&D, Inc. |
| Drug class | Sodium-activated potassium channel inhibitor |
| Target | Nav1.5 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
TV-46000 is a selective inhibitor of the sodium-activated potassium channel, Nav1.5, which plays a key role in the pathophysiology of atrial fibrillation. By inhibiting this channel, TV-46000 is expected to reduce the frequency of atrial fibrillation episodes and improve symptoms.
Approved indications
- Atrial fibrillation for stroke prevention
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
- Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia (PHASE3)
- A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |